TheragenEtex Develops Ultra-sensitive COVID-19 RNA Analysis System
On April 20, Theragen Bio (CEO and President Samuel(Taesoon) Hwang) announced that the company had developed and started offering a next-generation sequencing-based (NGS-based) COVID-19 ribonucleic acid (RNA) analysis system.
While other test kits detect and analyze three COVID-19 virus genes, this developed system can analyze 30,000 full-length COVID-19 RNA sequences.
More specifically, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a strain of coronavirus that causes COVID-19, is unstable and often results in mutations. This system can check RNA’s mutation, replication, and generation.
Not only can it be used to diagnose COVID-19, but it can also be used to develop treatments or vaccines and supplement epidemiological investigations on the sources of infection.
Furthermore, its advantage is that it can test thousands of samples for those who are asymptomatic or have the reactivated virus, which requires a high level of sensitivity and accuracy. It takes 2-3 days to analyze even with a trace amount of sample.